Lubiprostone
- Generic Name
- Lubiprostone
- Brand Names
- Amitiza
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32F2O5
- CAS Number
- 136790-76-6
- Unique Ingredient Identifier
- 7662KG2R6K
- Background
Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften the st...
- Indication
Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain. It is also indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in female patients ≥18 years old.
- Associated Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C), Opioid Induced Constipation (OIC), Chronic idiopathic constipation (CIC)
- Associated Therapies
- -
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
- Conditions
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 590
- Registration Number
- NCT00380250
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.